Clinical Trial Update: Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting Phase 1/2 evaluation of icotinib combined with whole-brain radiotherapy in EGFR-mutant non-small cell lung cancer with brain met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small Cell Lung Cancer, Brain Metastases | Phase 1, Phase 2 | Status: COMPLETED